BROOKS vs LASA: Stock Comparison

Brooks Laboratories Limited vs Lasa Supergenerics Limited

Live data: 16 April 2026, 4:01 PM IST • Source: NSE and company filings

Brooks Laboratories Limited is the larger company by market capitalisation. Brooks Laboratories Limited shows a higher ROE, lower leverage and a higher ROCE, while Lasa Supergenerics Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Brooks Laboratories Limited and Lasa Supergenerics Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BROOKS is more favourable on 8 of 11 scored metrics and LASA on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BROOKS is the larger company
₹185 Cr vs ₹35 Cr
EPS
BROOKS has higher earnings per share
₹7.32 vs ₹-6.8
Revenue Growth (TTM YoY)
LASA has faster revenue growth
0% vs -6.37%
Qtr Sales Growth
BROOKS has stronger quarterly sales growth
42.3% vs -100%
Qtr Profit Growth
BROOKS has stronger quarterly profit growth
498% vs -139%
ROE
BROOKS has a higher ROE
20.04% vs -19.6%
ROCE
BROOKS has a higher ROCE
-9.93% vs -18.2%
Net Margin
BROOKS has a higher net margin
28.67% vs -135.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBROOKSLASA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBROOKSLASA
Live Price₹69.58₹6.86
Day Change-3.45%0.59%
Volume91,9999,685
52-Week High₹163.9₹14.08
52-Week Low₹36.3₹5.67
Distance from 52W High-57.55%-51.28%

Valuation

MetricBROOKSLASA
Market Cap₹185 Cr₹35 Cr
P/E Ratio8.22x
P/B Ratio1.65x
EPS₹7.32₹-6.8
Book Value₹33.3₹9.89
Dividend Yield0%0%

Growth

MetricBROOKSLASA
Revenue Growth (TTM YoY)-6.37%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth42.3%-100%
Qtr Profit Growth498%-139%

Profitability & Leverage

MetricBROOKSLASA
ROE20.04%-19.6%
ROCE-9.93%-18.2%
Net Margin28.67%-135.6%
Operating Margin7.74%-29.3%
Debt to Equity0.06x0.2x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBROOKSLASA
Promoter Holding52.62%53.65%
FII Holding0% 0.17 pp0%
DII Holding10.38%0%
Public Holding37% 0.16 pp46.35%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Brooks Laboratories Limited and Lasa Supergenerics Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.